HIV-associated facial lipoatrophy

Dermatologic Surgery

Volumn 28, Issue 11, 2002, Pages 979-986

  James, Julia ^a   Carruthers, Alastair ^a,b   Carruthers, Jean ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Carruthers Dermatology Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; FIBRIC ACID DERIVATIVE; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG POTENCY; ERECTILE DYSFUNCTION; FACE; GALLSTONE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; LITERATURE; LIVER TOXICITY; MYOPATHY; MYOSITIS; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; RASH; SELF ESTEEM; SIDE EFFECT; SOCIALIZATION; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FACE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPECTOMY; RISK FACTORS;

EID: 0036860765     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2002.02099.x     Document Type: Article

References (55)

1. Ho TTY, Chan KCW, Wong KH, Lee SS. Indinavir-associated facial lipoatrophy in HIV-infected patients. AIDS Patient Care Stds 1999;13:11-6.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
3. Norbiato G, Trifiro G, Galli M, Gervasoni C, Clerici M. Fat redistribution in HIV-infected patients: A new hormonal-immune disorder? Ann N Y Acad Sci 2000;917:951-5.
4. Paparizos VA, Kyriakis KP, Botsis C, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS 2000;14:903-5.
5. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chrisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-9.
7. Rodwell GEJ, Maurer TA, Berger TG. Fat redistribution in HIV disease. J Am Acad Dermatol 2000;42:727-30.
8. Chastain MA, Chastain JB, Coleman WP. HIV lipodystrophy: Review of the syndrome and report of a case treated with liposuction. Dermatol Surg 2001;27:497-500.
9. Shaw AJ, McLean KA, Evans BA. Disorders of fat distribution in HIV infection. Int J STD AIDS 1998;9:595-9.
10. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J AIDS 2000;25:312-21.
11. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic Abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-39.
12. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000;30(suppl 2):S135-42.
13. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-F39.
14. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
15. Bonnet E, Ruidavets J-B, Tuech J, et al. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy. J Clin Endocrinol Metab 2000;86:296-302.
16. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
17. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-F32.
18. Carr A, Samaras K, Chrisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998;352:1881-3.
19. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
20. Côté HCF, Brumme ZL, Craib KJP, et al. Changes in Mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20.
21. Renard E, Fabre J, Paris F, Reynes J, Bringer J. Syndrome of body fat redistribution in HIV-1-infected patients: Relationships to cortisol and catecholamines. Clin Endocrinol 1999;51:223-30.
22. Christeff N, Nunez EA, Gougeon M-L. Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy. Ann N Y Acad Sci 2000;917:962-70.
23. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader 2000;10:546-51.
24. Wolfort FG, Cetrulo CL, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg 1999;104:1814-20.
25. Jones D. Commentary on HIV lipodystrophy. Dermatol Surg 2001;27:610.
26. Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
27. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrect M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13:2099-103.
28. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031-2.
29. Wood AJJ. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511.
30. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome. JAMA 2000;284:472-7.
31. Gold J, Batterham M. Nandrolone decanoate: Use in HIV-associated lipodystrophy syndrome: A pilot study. Int J STD AIDS 1999;10:558.
32. O'Mahony C, Price LM, Nelson M. Lipodystrophy despite anabolic steroids. Int J STD AIDS 1998;9:619.
33. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-78.
34. Rees T, Ashley FL. Treatment of facial atrophy with liquid silicone. AmJ Surg 1966;111:531-5.
35. Rees T, Ashley FL, Delgado JP. Silicone fluid injections for facial atrophy. Plast Reconstr Surg 1972;52:118-27.
36. Rees T, Coburn RJ. Silicone treatment of partial lipodystrophy. JAMA 1974;11:868-70.
37. Pollack SV. Silicone, fibrel, and collagen implantation for facial lines and wrinkles. J Dermatol Surg Oncol 1990;16:957-61.
38. Klein AW, Rish DC. Substances for soft tissue augmentation: Collagen and silicone. J Dermatol Surg Oncol 1985;11:337-9.
39. Kamer FM, Churukian MM. Clinical use of injectable collagen: A three-year retrospective review. Arch Otolaryngol 1984;110:93-8.
40. Overholt MA, Tschen JA, Font RL. Granulomatous reaction to collagen implant: Light and electron microscopic observations. Cutis 1993;51:95-8.
41. Rudolph CM, Soyer HP, Schuller-Petrovic S, Kerl H. Foreign body granulomas due to injectable aesthetic microimplants. Am J Surg Pathol 1999;23:113-7.
42. Moscona RR, Bergman R, Friedman-Birnbaum R. An unusual late reaction to Zyderm I injections: A challenge for treatment. Plast Reconstr Surg 1992;92:331-4.
43. Shore JW. Injectable lyophilized particulate human fascia lata (Fascian) for lip, perioral, and glabellar enhancement. Ophthalmic Plast Reconstr Surg 1999;16:23-7.
44. Burres S. Soft-tissue augmentation with Fascian. Clin Plast Surg 2001;1:101-10.
45. Maas CS, Eriksson T, McCalmont T, Mabry D, Cooke D, Schindler R. Evaluation of expanded polytetrafluoroethylene as a soft tissue filling substance: An analysis of design-related implant behavior using the porcine skin model. Plast Reconstr Surg 1998;101:1307-14.
46. Cisneros JL, Singla R. Intradermal augmentation with expanded polytetrafluoroethylene (GoreTex) for facial lines and wrinkles. J Dermatol Surg Oncol 1993;19:539-42.
47. Artz JS, Dinner MI. The use of expanded polytetrafluoroethylene as a permanent filler and enhancer: An early report of experience. Ann Plast Surg 1993;32:457-62.
48. Sherris DA, Larrabee WF. Expanded polytetrafluoroethylene augmentation of the lower face. Laryngoscope 1996;106:658-63.
49. Lassus C. Expanded PTFE in the treatment of facial wrinkles. Aesthetic Plast Surg 1991;15:167-74.
50. Mole B. The use of Gore-Tex implants in aesthetic surgery of the face. Plast Reconstr Surg 1991;90:200-6.
51. Klatt EC. Surgery and human immunodeficiency virus infection: Indications, pathologic findings, risks, and risk prevention. Int Surg 1994;79:1-5.
52. Kiene K, Hsu B, Rowe D, Carruthers A. Hepatitis, HIV and the dermatologist: A risk review. J Am Acad Dermatol 1994;30:108-15.
53. Bender BS, Bender JS. Surgical issues in the management of the HIV-infected patient. Surg Clin N Am 1993;73:373-88.
54. Roenigk HH, Crane G. AIDS and infection control in dermatologic surgery. Dermatol Clin 1991;9:579-84.
55. Gerberding JL. Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996;125:497-501.